[미국특허]
METFORMIN GLYCINATE, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME
원문보기
IPC분류정보
국가/구분
United States(US) Patent
공개
국제특허분류(IPC7판)
A61K-031/155
A61P-003/10
A61K-009/00
A61K-031/135
A61K-031/17
A61K-031/403
A61K-031/4439
A61K-031/444
A61K-031/495
A61K-031/4985
A61K-031/513
A61K-031/522
A61K-031/573
A61K-038/22
A61K-038/28
출원번호
17516961
(2021-11-02)
공개번호
20220296539
(2022-09-22)
발명자
/ 주소
GONZÁLEZ-CANUDAS, Jorge
출원인 / 주소
GONZÁLEZ-CANUDAS, Jorge
인용정보
피인용 횟수 :
0인용 특허 :
0
초록▼
The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide leve
The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed.
대표청구항▼
1.-10. (canceled) 11. A method of treating diabetes comprising administering to a subject in need thereof a therapeutically effective amount metformin glycinate in combination with one or more additional antidiabetic agents. 12. The method of claim 11, wherein the one or more additional antidiabetic
1.-10. (canceled) 11. A method of treating diabetes comprising administering to a subject in need thereof a therapeutically effective amount metformin glycinate in combination with one or more additional antidiabetic agents. 12. The method of claim 11, wherein the one or more additional antidiabetic agents are selected from the group consisting of a sulfonylurea, a thiazolidinedione, a dipeptidyl peptidase 4 (DPP4) inhibitor, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, a glucagon-like peptide-1 (GLP1) receptor agonist, glucagon like peptide-1 (GLP-1), and insulin. 13-20. (canceled) 21. The method of claim 11, wherein the metformin glycinate and the one or more additional antidiabetic agents are administered concurrently. 22. The method of claim 11, wherein the metformin glycinate and the one or more additional antidiabetic agents are administered orally. 23. The method of claim 21, wherein the metformin glycinate and the one or more additional antidiabetic agents are in the same dosage form. 24. The method of claim 11, wherein the metformin glycinate is administered once daily or twice daily. 25. The method of claim 11, wherein the treatment reduces the blood glycated hemoglobin (HbA1c) level in the subject to ≤7%. 26.-52. (canceled) 53. A pharmaceutical composition comprising (i) metformin glycinate; and(ii) (a) one or more antidiabetic agents; (b) an antihistamine selected from the group consisting of loratadine, diphendydramine, and cetirizine; (c) a steroid selected from the group consisting of betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone; or (d) a bronchodilator selected from the group consisting of salbutamol and salmeterol. 54. The pharmaceutical composition of claim 53, wherein the one or more antidiabetic agents is selected from the group consisting of a sulfonylurea, a thiazolidinedione, a DPP4 inhibitor, a SGLT2 inhibitor, a GLP1 receptor agonist, GLP-1, and insulin. 55.-61. (canceled) 62. The pharmaceutical composition of claim 54, wherein the DPP4 inhibitor is sitagliptin, saxagliptin, linagliptin, or alogliptin. 63. The pharmaceutical composition of 62, wherein the composition comprises from about 2.5 mg to about 100 mg of the DPP4 inhibitor. 64. The pharmaceutical composition of claim 54, wherein the thiazolidinedione is rosiglitazone. 65.-77. (canceled) 78. The pharmaceutical composition of claim 53, comprising metformin glycinate and an antihistamine selected from the group consisting of loratadine, diphendydramine, and cetirizine. 79. The pharmaceutical composition of claim 53, comprising metformin glycinate and a steroid selected from the group consisting of betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone. 80. The pharmaceutical composition of claim 53, comprising metformin glycinate and a bronchodilator selected from the group consisting of salbutamol and salmeterol. 81. The method of claim 12, wherein the DPP4 inhibitor is sitagliptin, saxagliptin, linagliptin, or alogliptin. 82. The method of claim 12, wherein the thiazolidinedione is rosiglitazone. 83. The method of claim 12, wherein the sulfonylurea is glimepiride, glipizide, or glyburide. 84. The method of claim 12, wherein the SGLT2 inhibitor is canagliflozin or dapagliflozin. 85. The method of claim 12, wherein the one or more additional antidiabetic agents comprise insulin.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.